Boston Scientific (BSX) Tops Q2 EPS by 1c; Boosts FY15 Revenue Outlook

Boston Scientific (NYSE: BSX) reported Q2 EPS of $0.22, $0.01 better than the analyst estimate of $0.21. Revenue for the quarter came in at $1.84 billion versus the consensus estimate of $1.83 billion.

"Our strong performance in the second quarter reflects the consistent execution of our global teams," said Mike Mahoney, president and chief executive officer, Boston Scientific. "We are particularly pleased with the improved growth in MedSurg and continued strength in Cardiovascular. We look forward to continued momentum with several ongoing product launches and the planned closing of the American Medical Systems (AMS) urology portfolio acquisition in the third quarter of 2015."

Boston Scientific sees FY2015 revenue of $7.275-7.375 billion, versus prior guidance of $7.225-7.375 billion and the consensus of $7.34 billion.

Boston Scientific sees Q3 2015 EPS of $0.21-$0.23, versus the consensus of $0.23. Boston Scientific sees Q3 2015 revenue of $1.79-1.84 billion, versus the consensus of $1.84 billion.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.

You May Also Be Interested In

• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• Five9 names new CTO, chief sales officer, and EVP of strategy